详细的全球迷幻医学市场研究报告2025
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Psychedelic Medicine Market Size Growth Rate by Type: 2019 VS 2025 VS 2033
1.2.2 Psilocybin
1.2.3 LSD
1.2.4 MDMA
1.2.5 DMT
1.2.6 Ketamine
1.2.7 Others
1.3 Market by Application
1.3.1 Global Psychedelic Medicine Market Growth by Application: 2019 VS 2025 VS 2033
1.3.2 Depressive Disorders
1.3.3 Post-Traumatic Stress Disorders
1.3.4 Substance Abuse Disorders
1.3.5 Obsessive Compulsive Disorders
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2全球增长趋势
2.1全球迷幻医学市场的市场观点（2019-2033）
2.2 2.2迷幻医学增长趋势按地区按地区划分
2.2.1全球迷幻医学市场规模按地区划分：2019 vs 2025 vs 2025 vs 2033 vs 2033
2.2.2.2.2.2.2.2.2.2.2.2.2 (2025-2033)
2.3 Psychedelic Medicine Market Dynamics
2.3.1 Psychedelic Medicine Industry Trends
2.3.2 Psychedelic Medicine Market Drivers
2.3.3 Psychedelic Medicine Market Challenges
2.3.4 Psychedelic Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Psychedelic Medicine Players by Revenue
3.1.1 Global Top通过收入（2019-2025）
3.1.2球员（2019-2025）全球迷幻医学收入市场份额（2019-2025）
3.2 3.2全球迷幻医学市场份额按公司类型（Tier 1，Tier 2和Tier 3和Tier 3）
3.3涵盖的全球迷幻药市场份额
3.3 Psychedelic Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Psychedelic Medicine Revenue in 2025
3.5 Psychedelic Medicine Key Players Head office and Area Served
3.6 Key Players Psychedelic Medicine Product Solution and Service
3.7 Date of Enter into Psychedelic Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Psychedelic Medicine按类型按类型进行细分数据
4.1全球迷幻药的历史市场规模（2019-2025）
4.2 4.2全球迷幻药预测的市场规模（2025-2033）
5 5 5.1通过应用程序划分的全球性药物范围（2019-20-20-2.2.2） （2025-2033）
6北美
6.1北美迷幻医学市场规模（2019-2033）
6.2北美北美迷幻医学的市场增长率按国家 /地区：2019 vs 2025 vs 2033 vs 2033
6.3北美药物市场大小划分国家 /地区（2019-2025）北美
6.4北美
（2025-2033）
6.5美国
6.6加拿大
7欧洲
7.1欧洲迷幻医学的医学市场规模（2019-2033）
7.2欧洲迷幻医学市场增长率按国家 /地区按国家 /地区按国家 /地区划分的欧洲，欧洲迷幻医学的市场规模，划分2019年，欧洲（2019-2025） （2025-2033）
7.5德国
7.6法国
英国7.7英国
7.8意大利
7.9俄罗斯
7.10北欧国家
8 Asia-Pacific
8.1 8.1 8.1 8.1 Asia-aia-Pacific Pastedific Medicinic Medicine Market尺寸 2033
8.3 Asia-Pacific Psychedelic Medicine Market Size by Region (2019-2025)
8.4 Asia-Pacific Psychedelic Medicine Market Size by Region (2025-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America迷幻药市场的市场规模（2019-2033）
9.2拉丁美洲迷幻医学市场增长率按国家 /地区划分：2019 vs 2025 vs 2033
9.3拉丁美洲美国迷幻医学市场规模划分国家 /地区（2019-2025）
9.4拉丁美洲的迷幻药物市场大小，划分国家 /地区（2025-20333333333333）巴西
10中东和非洲
10.1中东和非洲迷幻医学市场规模（2019-2033）
10.2中东和非洲的非洲迷幻药市场增长率按国家 /地区：2019 vs 2025 vs 2033 vs 2033 vs 2033
10.3中东和非洲的中东和非洲跨国医学划分的国家 /地区的尺寸（2019-20-20-20-20-2025） （2025-2033）
10.5土耳其
10.6沙特阿拉伯
10.7阿联酋
11个主要参与者
11.1 Compass Pathways
11.1 Compass Pathways plc
11.1.1 Compass Pathways Plc Pathways PLC Company plc Company plc Company详细信息在迷幻医学业务（2019-2025）
11.1.5 Compass Pathways PLC最新发展
11.2 Pfizer
11.2.1 Pfizer Company详细信息
11.2.2 Pfizer商业概述
11.2.2.2.3最近的发展
11.3 Eli Lilly
11.3.1 Eli Lilly Company详细信息
11.3.2 Eli Lilly商业概述
11.3.3 Eli Lilly Lilly Psychedelic Medicine介绍
11.3.4 Eli Lilly Lilly Lilly在迷幻医学商业中的收入 GlaxoSmithKline Company Detail
11.4.2 GlaxoSmithKline Business Overview
11.4.3 GlaxoSmithKline Psychedelic Medicine Introduction
11.4.4 GlaxoSmithKline Revenue in Psychedelic Medicine Business (2019-2025)
11.4.5 GlaxoSmithKline Recent Development
11.5 Cybin Inc
11.5.1 Cybin Inc Company细节
11.5.2 Cybin Inc业务概述
11.5.3 Cybin Inc迷幻医学简介
11.5.4 Cybin Inc在迷幻医学业务中收入（2019-2025）
11.5.5 Cybin Inc Cybin Inc最近开发的最新发展
11.6实地考察健康
11.6实地考察健康
11.6.6 Field Trip Trip Comparate
Bive Company Company
11.1 Field Comparate Comparation
11.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.66.66.6 6.6 6.66.6 6.6 6.66。 Overview
11.6.3 Field Trip Health Psychedelic Medicine Introduction
11.6.4 Field Trip Health Revenue in Psychedelic Medicine Business (2019-2025)
11.6.5 Field Trip Health Recent Development
11.7 ATAI Life Sciences
11.7.1 ATAI Life Sciences Company Detail
11.7.2 ATAI Life Sciences Business Overview
11.7.3 ATAI Life Sciences Psychedelic Medicine Introduction
11.7.4 ATAI Life Sciences Revenue in Psychedelic Medicine Business (2019-2025)
11.7.5 ATAI Life Sciences Recent Development
11.8 NUMINUS WELLNESS
11.8.1 NUMINUS WELLNESS Company Detail
11.8.2 NUMINUS WELLNESS Business Overview
11.8.3 NUMINUS WELLNESS Psychedelic Medicine Introduction
11.8.4 NUMINUS WELLNESS Revenue in Psychedelic Medicine Business (2019-2025)
11.8.5 NUMINUS WELLNESS Recent Development
11.9 MindMed
11.9.1 MindMed Company Detail
11.9.2 MindMed Business Overview
11.9.3 MindMed Psychedelic Medicine Introduction
11.9.4 MindMed Revenue in Psychedelic Medicine Business (2019-2025)
11.9.5 MindMed Recent Development
11.10 HAVN Life Sciences
11.10.1 HAVN Life Sciences Company Detail
11.10.2 HAVN Life Sciences Business Overview
11.10.3 HAVN Life Sciences Psychedelic Medicine Introduction
11.10.4 HAVN Life Sciences Revenue in Psychedelic Medicine Business (2019-2025)
11.10.5 HAVN Life Sciences Recent Development
11.11 Seelos Therapeutics
11.11.1 Seelos Therapeutics Company Detail
11.11.2 Seelos Therapeutics Business Overview
11.11.3 Seelos Therapeutics Psychedelic Medicine Introduction
11.11.4 Seelos Therapeutics Revenue in Psychedelic Medicine业务（2019-2025）
11.11.5 Seelos Therapeutics最近的开发
11.12 Jannsen
11.12.1 Jannsen Company详细信息
11.12.2 Jannsen商业概述（2019-2025）
11.12.5 Jannsen最近的开发
11.13 Acadia Pharmaceuticals
11.13.1 Acadia Pharmaceuticals Company详细信息
11.13.2 Acadia Pharmaceuticals商业概述
11.13.13.13.13.13.3 Acadia Pharmaceuticals Pharmaceuticals Pssshieticals Pssshietical Intersion Pression in Cression
11.1.1.1.1.1.13.4.13.4.4.13.4.4.13.44.44.4.13.44.44.4.13.4.44 (2019-2025)
11.13.5 Acadia Pharmaceuticals Recent Development
11.14 Intellipharmaceutics
11.14.1 Intellipharmaceutics Company Detail
11.14.2 Intellipharmaceutics Business Overview
11.14.3 Intellipharmaceutics Psychedelic Medicine Introduction
11.14.4 Intellipharmaceutics Revenue in Psychedelic Medicine Business (2019-2025)
11.14.5 Intellipharmaceutics Recent Development
11.15 Revive Therapeutics
11.15.1 Revive Therapeutics Company Detail
11.15.2 Revive Therapeutics Business Overview
11.15.3 Revive Therapeutics Psychedelic Medicine Introduction
11.15.4 Revive Therapeutics Revenue in Psychedelic Medicine Business (2019-2025)
11.15.5 Revive Therapeutics Recent Development
11.16 Mydecine Innovations Group
11.16.1 Mydecine Innovations Group Company Detail
11.16.2 Mydecine Innovations Group Business Overview
11.16.3 Mydecine Innovations Group Psychedelic Medicine Introduction
11.16.4 Mydecine Innovations Group Revenue in Psychedelic Medicine Business (2019-2025)
11.16.5 Mydecine Innovations Group Recent Development
11.17 Red Light Holland
11.17.1 Red Light Holland Company Detail
11.17.2 Red Light Holland Business Overview
11.17.3 Red Light Holland Psychedelic Medicine Introduction
11.17.4 Red Light Holland Revenue in Psychedelic Medicine Business (2019-2025)
11.17.5 Red Light Holland Recent Development
11.18 Braxia Scientific
11.18.1 Braxia Scientific Company Detail
11.18.2 Braxia Scientific Business Overview
11.18.3 Braxia Scientific Psychedelic Medicine Introduction
11.18.4 Braxia Scientific Revenue in迷幻医学业务（2019-2025）
11.18.5 Braxia Scientific最近的发展
11.19 Mind Cor Cure Health
11.19.1 Mind Cure Health Company Company Company详细信息
11.19.2 Mind Cure Health Business概述（2019-2025）
11.19.5心理治疗健康最近的发展
11.20 Entheon BioMedical
11.20.1 Entheon BioMedical Company详细信息
11.20.2 Entheon BioMedical Biomedical Business oferview
11.20.20.20.3 (2019-2025)
11.20.5 Entheon Biomedical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
